{"organizations": [], "uuid": "7d2b8b3462f872b105a4dd9ec7f9279f918a31f0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180116.html", "section_title": "Archive News &amp; Video for Tuesday, 16 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-ipsen-and-exelixis-announce-phase/brief-ipsen-and-exelixis-announce-phase-3-trial-results-of-cabozantinib-showing-benefit-in-hepatocellular-carcinoma-patients-idUSFWN1PB1C0", "country": "US", "domain_rank": 408, "title": "BRIEF-Ipsen And Exelixis Announce Phase 3 Trial Results Of Cabozantinib Showing Benefit In Hepatocellular Carcinoma Patients", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.744, "site_type": "news", "published": "2018-01-17T06:06:00.000+02:00", "replies_count": 0, "uuid": "7d2b8b3462f872b105a4dd9ec7f9279f918a31f0"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ipsen-and-exelixis-announce-phase/brief-ipsen-and-exelixis-announce-phase-3-trial-results-of-cabozantinib-showing-benefit-in-hepatocellular-carcinoma-patients-idUSFWN1PB1C0", "ord_in_thread": 0, "title": "BRIEF-Ipsen And Exelixis Announce Phase 3 Trial Results Of Cabozantinib Showing Benefit In Hepatocellular Carcinoma Patients", "locations": [], "entities": {"persons": [{"name": "ipsen", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "exelixis announce phase", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "exelixis", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 16 (Reuters) - IPSEN SA:\n* EXELIXIS AND IPSEN ANNOUNCE PHASE 3 TRIAL RESULTS OF CABOZANTINIB DEMONSTRATING SIGNIFICANT OVERALL SURVIVAL BENEFIT IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA\n* IN CELESTIAL, CABOZANTINIB PROVIDED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT VERSUS PLACEBO IN OVERALL SURVIVAL\n* MEDIAN OS WAS 10.2 MONTHS WITH CABOZANTINIB VERSUS 8.0 MONTHS WITH PLACEBO Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-17T06:06:00.000+02:00", "crawled": "2018-01-17T19:45:03.012+02:00", "highlightTitle": ""}